Healthcare Providers and Services
Company Overview of Fox Chase Cancer Center
Fox Chase Cancer Center operates as a cancer research and treatment center in the United States. It provides diagnostic, treatment, research, and prevention services in the areas of breast, colon, lung, and prostate cancer. The company also provides breast evaluation, risk assessment, and diagnostic imaging services; and breast, gynecologic, and ovarian cancer research programs. In addition, it offers screening services, including prevention screening, mammography, skin cancer, Barrett’s esophagus, and open access endoscopy services. Further, the company conducts basic, translational, and clinical research with special programs in cancer prevention, detection, survivorship, and community out...
333 Cottman Avenue
Philadelphia, PA 19111-2497
Founded in 1904
Key Executives for Fox Chase Cancer Center
Chief Financial Officer and Senior Vice President
Chief Operating Officer and Senior Vice President
President of Trading Post Chapter
President of Marlyn R. Fein Chapter
Compensation as of Fiscal Year 2014.
Fox Chase Cancer Center Key Developments
Fox Chase Cancer Center Appoints Richard I. Fisher as President and CEO
Aug 4 13
Richard I. Fisher, MD has been appointed President and CEO of Fox Chase Cancer Center. Fisher will also hold the title of Cancer Center Director of Fox Chase, serving as the principal investigator on the Cancer Center Support Grant (CCSG) from the National Cancer Institute. He will retain the title of Senior Associate Dean for Cancer Programs at Temple University School of Medicine. Since his arrival, Kaiser noted, Fisher has demonstrated extraordinarily adroit and sure-handed leadership and administrative ability, working closely with leaders at Fox Chase and across Temple Health. He has helped to advance a positive and forward-looking perspective that will help to reinvigorate clinical and scientific cancer programs and to launch vital faculty recruitment efforts. Before joining Fox Chase and Temple Health, Fisher was Vice President for Strategic and Program Development at the University of Rochester Medical Center and the Samuel E. Durand Professor of Medicine.
Fox Chase Cancer Center Hires Richard I. Fisher as Executive Vice President
Mar 25 13
Richard I. Fisher has been hired as executive vice president at Fox Chase Cancer Center, responsible for overseeing and leading the seven clinical-department chairs at the center, a member of the Temple University Health System and Temple University School of Medicine. Fisher had been vice president for strategic and program development at the University of Rochester Medical Center, where he was also Samuel E. Durand professor of medicine.
Fox Chase Cancer Center Announces Offering of New Clinical Test CancerCode-45(TM)
Jan 7 13
Fox Chase Cancer Center offering patients with advanced cancer a cutting-edge clinical test that will provide them with a unique blueprint of their cancer genes. The new clinical test, known as CancerCode-45(TM), evaluates an individual's tumor for genetic alterations in a select group of 45 genes and gives physicians the opportunity to look at the alterations and be even more precise when choosing a course of treatment. The test is being offered through the Cancer Genome Institute at Fox Chase one of only a few centers in the nation to offer such pioneering technology in cancer molecular diagnostics. Using leading-edge technology, physicians and scientists at Fox Chase are able to perform the CancerCode-45 test and analyze the genetic information in the DNA of a patient's tumor to find changes that are crucial to supporting their cancer. This genetic analysis will examine multiple alterations in 45 cancer-related genes and provide a report to the patient's treating physician. Prior to the CancerCode-45 test being performed, patients will need to see a Fox Chase physician to provide information about their background, medical history, current medications, and ability to perform daily activities. In addition, the physician will need to take a blood sample and a sample of the tumor (which can come from a previous surgery or biopsy that the patient might have had). It takes about 20 working days to get each patient's test results.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|